CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approvals from the USFDA for Isosorbide Dinitrate Tablets and Desonide Cream21-11-2019
21-11-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus announces second Phase 3 trial of Desidustat18-11-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives tentative approval from the USFDA for Apremilast Tablets16-11-2019
Cadila Healthcare shares rise over 3% on acquiring remaining stake in 2 subsidiaries
Following the acquisition of the remaining 15% stake each in its subsidiaries Zydus Technologies Ltd and Zydus Noveltech Inc, the two companies will become wholly-owned subsidiaries of Cadila Healthcare Ltd14-11-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Acquisition
Acquisition of shares of subsidiary companies.13-11-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release for unaudited financial results 30 09 201913-11-2019
Cadila Healthcare Ltd - 532321 - Unaudited Financial Results September 30 2019
Unaudited financial results for the quarter / half year ended on Septemebr 30, 201913-11-2019
Cadila Healthcare Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate / issue of duplicate share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)08-11-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Interaction and Call on November 13, 201906-11-2019
CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificates06-11-2019